N91115 is a novel inhibitor of S-nitrosoglutathione
N30 Pharma has developed a novel portfolio of GSNOR inhibitor drugs that conserve S-nitrosoglutathione
(GSNO), an endogenous, signaling molecule that has been shown to modulate the function of key proteins involved in the pathophysiology of CF through S-nitrosation.
N6022 is the first of a novel class of N30 Pharma's drugs aimed at conservation of S-nitrosoglutathione
(GSNO) a key, endogenous, signaling molecule that has been shown to be reduced in cystic fibrosis patients.
N6022, a novel modulator of s-nitrosoglutathione
reductase, is the lead product in N30 Pharma's portfolio of drugs, recently completed Phase 2a testing, and is currently in preparation for clinical testing in the F508del mutation of Cystic Fibrosis.
The data describe the preclinical safety evaluation of small molecule inhibitors of S-nitrosoglutathione
reductase (GSNOR), and the lack of apparent mechanism-based toxicities.
N6022, a first-in-class inhibitor of s-nitrosoglutathione
reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
N30 drugs target s-nitrosoglutathione
reductase (GSNOR), the only druggable enzyme that consumes s-nitrosoglutathione
(GSNO), a central regulator of the endogenous nitric oxide pool.
N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione
(GSNO), an endogenous bronchodilatory molecule that serves as a critical store of nitric oxide (NO) bioactivity in the human airway.